Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-Small Cell Lung Cancer · Sarcoma · Head &Amp; Neck Cancer · Colorectal Carcinoma · Endometrial
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Institut de Cancérologie de l'Ouest, Angers, France
Chu Timone, Marseille, France
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
Gustave Roussy, Villejuif, France
Contact: Study coordinator (Barbara PISTILLI, Dr) · barbara.pistilli@gustaveroussy.fr · +33 (0)1 42 11 61 62
Study leads
Barbara PISTILLI, Dr
Principal Investigator
Gustave Roussy, VILLEJUIF